| 赵琳娜,李洪艳,张 威,刘 丽,武 文,董雪斌,孙文才.昆仙胶囊联合来氟米特治疗狼疮性肾炎临床疗效的回顾性研究[J].,2022,(8):1489-1493 |
| 昆仙胶囊联合来氟米特治疗狼疮性肾炎临床疗效的回顾性研究 |
| Retrospective Study on the Clinical Efficacy of Kunxian Jiaonang Combined with Leflunomide in the Treatment of Lupus Nephritis |
| 投稿时间：2021-09-03 修订日期：2021-09-26 |
| DOI：10.13241/j.cnki.pmb.2022.08.018 |
| 中文关键词: 昆仙胶囊 来氟米特 狼疮性肾炎 疗效 肾功能 |
| 英文关键词: Kunxian Jiaonang Leflunomide Lupus nephritis Efficacy Renal function |
| 基金项目:河北省张家口市重点研发计划项目(1921118D)；河北省自然科学基金项目(H2015105041) |
|
| 摘要点击次数: 665 |
| 全文下载次数: 289 |
| 中文摘要: |
| 摘要 目的：探讨昆仙胶囊联合来氟米特对狼疮性肾炎患者的治疗效果。方法：回顾性分析2017年1月至2019年7月于本院接受治疗的120例狼疮性肾炎患者的临床资料，按照治疗方案的不同将其分为对照组（n=60）和观察组（n=60）。对照组给予来氟米特治疗，观察组在此基础上联合昆仙胶囊治疗。比较两组患者治疗后的疗效、狼疮疾病活动指数（SLEDAI）评分、肾功能和实验室指标、不良反应和复发情况。结果：治疗后，观察组总有效率为93.33%（56/60），高于对照组73.33%（44/60）（P<0.05）。治疗后，观察组患者24 h尿蛋白定量（24 h UP）、血肌酐（Scr）、SLEDAI评分、红细胞沉降率（ESR）、C反应蛋白（CRP）显著低于对照组，血浆白蛋白（Alb）、补体C3与C4水平显著高于对照组（P<0.05）；观察组的复发率（8.33%）以及不良反应发生率（13.33%）均显著低于对照组的23.33%、30.00%，差异具有统计学意义（P<0.05）。结论：昆仙胶囊联合来氟米特可以有效治疗狼疮性肾炎，明显改善患者病情活动度和肾功能，同时降低复发率和不良反应发生率，在临床上具有一定的应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the therapeutic effect of Kunxian Jiaonang combined with leflunomide in the treatment of lupus nephritis. Methods: The clinical data of 120 patients with lupus nephritis who were treated in our hospital from January 2017 to July 2019 were retrospectively analyzed. According to different treatment methods, all subjects were divided into control group (n=60) and observation group (n=60). The control group was treated with leflunomide, and the observation group was treated with Kunxian Jiaonang on this basis. The efficacy after treatment, lupus disease activity index (SLEDAI) score, renal function and laboratory indexes, adverse reactions and recurrence were compared between the two groups. Results: After treatment, the total effective rate in the observation group was 93.33% (56/60), which was higher than 73.33% (44/60) in the control group (P<0.05). After treatment, the levels of 24 h urinary protein (24 h UP), serum creatinine (Scr), SLEDAI score, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) of the observation group were significantly lower than those of the control group, and the plasma albumin (Alb), complement C3 and C4 levels were significantly higher than those of the control group(P<0.05). The recurrence rate (8.33%) and the incidence of adverse reactions (13.33%) of the observation group were significantly lower than 23.33% and 30.00% of the control group (P<0.05). Conclusion: Kunxian Jiaonang combined with leflunomide can effectively treat lupus nephritis, which can significantly improve patients' disease activity and renal function, and reduce the recurrence rate and incidence of adverse reactions. It has a certain clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
